查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972957

生长因子市场：市场洞察、竞争格局及市场预测（2033 年）

Growth Factors Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 200 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球生长因子市场预计将从 2026 年的 24 亿美元显着增长至 2033 年的 39 亿美元，复合年增长率 (CAGR) 高达 5.7%。这一增长主要得益于生物技术、药物研发和再生医学领域对生长因子的日益广泛应用，以及全球慢性病和癌症发病率的上升。

市场概览

生长因子是天然存在的蛋白质，能够调节细胞生长、增生和分化。它们在伤口癒合、组织再生和标靶治疗中发挥着至关重要的作用，使其成为现代生物医学研究和临床应用中不可或缺的工具。 它们在肿瘤学、血液学和再生医学领域的广泛应用，正推动其在研究和治疗流程中广泛应用。

重组DNA技术和蛋白质工程等技术的进步，使得高纯度生长因子的生产成为可能，提高了其在研究和商业应用中的功效和可用性。 製药和生技公司对蛋白质疗法的投资不断增加，进一步推动了市场的扩张。

市场驱动因素

推动该市场成长的因素如下：

  • 1. 慢性病和癌症发生率上升：随着全球癌症、心血管疾病和糖尿病发生率的上升，标靶治疗和再生医学解决方案的重要性日益凸显，对生长因子的需求也随之增长。
  • 2. 细胞疗法和再生医学的进步：生长因子在干细胞研究、组织工程和体外生产中促进细胞增殖和分化，推动了其在先进治疗应用中的应用。
  • 3.政府支持与资助：全球监管机构和政府都在资助生物技术和再生医学研究，促进生长因子在临床和研究领域的应用。
  • 4. 製药业研发投入的扩大：製药和生技公司正在增加对蛋白质疗法的投资，从而增强了研发项目对生长因子的需求。

商机

生长因子市场为製造商和投资者提供了许多充满前景的机会：

  • 创新疗法：生长因子对于再生医学、癌症治疗和伤口癒合产品的开发至关重要，这创造了巨大的研发和商业化机会。
  • 新兴市场成长：亚太和拉丁美洲不断扩大的医疗基础设施和研究计画为市场扩张提供了途径。
  • 策略合作：与研究中心、合约研究组织 (CRO) 和学术机构建立合作关係，可加速产品开发并增强市场影响力。

区域分析

  • 北美：得益于强大的製药和生物技术产业基础、完善的研究基础设施以及政府对先进疗法的资助，该市场处于领先地位。
  • 欧洲：在再生医学、蛋白质疗法的高普及率以及支持性监管框架的推动下，呈现稳定成长态势。
  • 亚太地区：预计成长速度最快，这主要得益于医疗保健支出的增加、生物技术生态系统的发展以及中国、日本和印度研究活动的拓展。
  • 拉丁美洲：医疗保健基础设施的改善、与全球生物技术公司合作的加强以及研究能力的提升，都为该地区的增长提供了支持。
  • 非洲：儘管规模较小，但由于人们对先进疗法的认识不断提高以及生物技术解决方案的日益普及，该市场正在稳步扩张。

主要参与者

市场竞争非常激烈，主要参与者专注于研发、产品开发和商业化。

主要公司包括：
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Hoffmann-La Roche Ltd.
  • Applied Biological Materials (abm), Inc.
  • Abcam plc
  • GE Healthcare
  • Cell Signaling Technology, Inc.
  • Meridian Bioscience Inc.
  • Sartorius CellGenix GmbH
  • Bio-Techne Corporation
  • Proteintech Group, Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • Akron Biotech
  • Sino Biological Inc.
  • Repligen Corporation
  • LEADGENE BIOMEDICAL, INC.
  • PeproTech Inc.

这些公司正在拓展产品组合，加大研发投入，并建立策略合作伙伴关係，以开发具有更高稳定性、特异性和治疗应用的下一代生长因子。

市场区隔

依产品类型：

  • 转化生长因子 (TGF)
  • 激活素
  • 骨形态发生蛋白 (BMP)
  • TGF-β 蛋白
  • 表皮生长因子 (EGF)
  • 血小板衍生生长因子 (PDGF)
  • 纤维母细胞生长因子 (FGF)
  • 类胰岛素生长因子 (IGF)
  • 血管内皮生长因子 (VEGF)
  • 肝细胞生长因子 (HGF)
  • 肿瘤坏死因子 (TNF)
  • 白血球介素
  • 其他

依应用:

  • 肿瘤学
  • 血液学
  • 伤口癒合
  • 皮肤病学
  • 心血管疾病与糖尿病
  • 细胞疗法与体外生产
  • 其他

依最终使用者划分：

  • 製药公司和生技公司
  • 研究中心和学术机构
  • 合约研发组织

依地区划分：

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

目录

第一章 摘要整理

第二章：市场概述

  • 市场定义与细分
  • 市场动态
    • 驱动因素
    • 限制因素
    • 市场机遇
  • 价值链分析
  • 新冠疫情影响分析
  • 波特五力分析
  • 俄乌衝突的影响
  • PESTLE分析
  • 监理分析
  • 价格趋势分析
    • 当前价格与未来预测（2025-2033年）
    • 价格影响因素

第三章 全球成长因素市场展望（2020-2033年）
  • 全球成长因素市场展望（依产品类型与价值划分，单位：十亿美元） 2020–2033
    • 转化生长因子 (TGF)
    • 表皮生长因子 (EGF)
    • 血小板衍生生长因子 (PDGF)
    • 纤维母细胞生长因子 (FGF)
    • 类胰岛素生长因子 (IGF)
    • 血管内皮生长因子 (VEGF)
    • 肝细胞生长因子 (HGF)
    • 肿瘤坏死因子 (TNF)
    • 白血球介素
    • 其他
  • 全球生长因子市场展望，依应用领域划分，价值（十亿美元），2020–2033 年（33 年）
    • 肿瘤学
    • 血液学
    • 伤口癒合
    • 皮肤病学
    • 心血管疾病与糖尿病
    • 细胞疗法与体外製造业
    • 其他
  • 全球成长因子市场展望（依最终用户划分，价值（十亿美元）），2020-2033 年
    • 製药和生技公司
    • 研究中心和学术机构
    • 合约研究公司
  • 全球成长因子市场展望（依地区划分，价值（十亿美元）），2020-2033 年
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第四章：北美成长因子市场展望，2020-2033 年

第五章：欧洲成长因子市场展望，2020-2033 年

第六章：亚太地区成长因子市场展望， 2020–2033

第七章：拉丁美洲成长因子市场展望，2020–2033

第八章：中东与非洲成长因子市场展望，2020–2033

第9章 竞争情形

  • 企业对市场区隔热图
  • 企业市场占有率分析，2025年
  • 竞争仪表板
  • 企业简介
    • Lonza Group AG
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Hoffmann-La Roche Ltd.
    • Applied Biological Materials (abm), Inc.
    • Abcam plc
    • GE Healthcare
    • Cell Signaling Technology, Inc.
    • Meridian Bioscience Inc.
    • Sartorius CellGenix GmbH

第10章 附录

简介目录

The global Growth Factors Market is anticipated to grow significantly, rising from $2.4 billion in 2026 to $3.9 billion by 2033, at a robust compound annual growth rate (CAGR) of 5.7%. This growth is primarily driven by the increasing adoption of growth factors in biotechnology, pharmaceutical research, and regenerative medicine, alongside the rising prevalence of chronic diseases and cancer worldwide.

Market Overview

Growth factors are naturally occurring proteins that regulate cellular growth, proliferation, and differentiation. They play a vital role in wound healing, tissue regeneration, and targeted therapeutics, making them essential tools in modern biomedical research and clinical applications. Their versatility in oncology, hematology, and regenerative medicine has driven widespread adoption across research and therapeutic pipelines.

Technological advancements, including recombinant DNA technology and protein engineering, have enabled the production of high-purity growth factors, improving their efficacy and availability for research and commercial applications. Increasing investments by pharmaceutical and biotechnology companies in protein-based therapeutics are further driving market expansion.

Market Drivers

Several factors are fueling growth in this market:

  • 1. Rising Chronic Disease and Cancer Incidence: The global increase in cancer, cardiovascular disorders, and diabetes is boosting demand for growth factors as targeted therapies and regenerative solutions gain importance.
  • 2. Advancements in Cell Therapy and Regenerative Medicine: Stem cell research, tissue engineering, and ex-vivo manufacturing require growth factors to enhance cell proliferation and differentiation, driving their adoption in advanced therapeutic applications.
  • 3. Government Support and Funding: Regulatory agencies and governments worldwide are funding biotechnology and regenerative medicine research, promoting the use of growth factors in clinical and research settings.
  • 4. Expansion of Pharmaceutical R&D: Pharmaceutical and biotechnology firms are increasingly investing in protein-based therapeutics, strengthening demand for growth factors across research and drug development programs.

Business Opportunities

The growth factors market presents several lucrative opportunities for manufacturers and investors:

  • Innovative Therapeutics: Growth factors are critical to developing regenerative therapies, cancer treatments, and wound healing products, creating significant opportunities for research and commercialization.
  • Emerging Market Growth: Increasing healthcare infrastructure and research initiatives in Asia Pacific and Latin America provide avenues for market expansion.
  • Strategic Collaborations: Partnerships with research centers, contract research organizations (CROs), and academic institutions can accelerate product development and strengthen market presence.

Regional Analysis

  • North America: Dominates the market due to a strong pharmaceutical and biotechnology ecosystem, well-established research infrastructure, and substantial government funding for advanced therapeutics.
  • Europe: Experiences steady growth driven by high adoption of regenerative therapies, protein-based therapeutics, and supportive regulatory frameworks.
  • Asia Pacific: Projected to grow at the fastest rate, fueled by increasing healthcare expenditure, a growing biotechnology ecosystem, and expanding research initiatives in China, Japan, and India.
  • Latin America: Growth is supported by improving healthcare infrastructure, rising collaborations with global biotech firms, and expanding research capabilities.
  • Middle East & Africa: Though smaller in size, the market is expanding steadily due to increasing awareness of advanced therapies and growing adoption of biotechnology-based solutions.

Key Players

The market is highly competitive, with key players focusing on research, product development, and commercialization. Leading companies include:

  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Hoffmann-La Roche Ltd.
  • Applied Biological Materials (abm), Inc.
  • Abcam plc
  • GE Healthcare
  • Cell Signaling Technology, Inc.
  • Meridian Bioscience Inc.
  • Sartorius CellGenix GmbH
  • Bio-Techne Corporation
  • Proteintech Group, Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • Akron Biotech
  • Sino Biological Inc.
  • Repligen Corporation
  • LEADGENE BIOMEDICAL, INC.
  • PeproTech Inc.

These companies are expanding portfolios, investing in R&D, and forming strategic collaborations to develop next-generation growth factors with enhanced stability, specificity, and therapeutic applications.

Market Segmentation

By Product Type:

  • Transforming Growth Factor (TGF)
  • Activin
  • Bone Morphogenetic Proteins (BMPs)
  • TGF-beta Proteins
  • Epidermal Growth Factors (EGFs)
  • Platelet-Derived Growth Factors (PDGFs)
  • Fibroblast Growth Factors (FGFs)
  • Insulin-like Growth Factors (IGFs)
  • Vascular Endothelial Growth Factors (VEGFs)
  • Hepatocyte Growth Factors (HGFs)
  • Tumor Necrosis Factors (TNFs)
  • Interleukins
  • Others

By Application:

  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease & Diabetes
  • Cell Therapy and Ex-Vivo Manufacturing
  • Others

By End User:

  • Pharmaceutical and Biotechnology Companies
  • Research Centres & Academic Institutes
  • Contract Research Organisations

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Growth Factors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Growth Factors Market Outlook, 2020-2033

  • 3.1. Global Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Transforming Growth Factor (TGF)
      • 3.1.1.1. Activin
      • 3.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 3.1.1.3. TGF-beta Proteins
    • 3.1.2. Epidermal Growth Factors (EGFs)
    • 3.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 3.1.4. Fibroblast Growth Factors (FGFs)
    • 3.1.5. Insulin-like Growth Factors (IGFs)
    • 3.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 3.1.7. Hepatocyte Growth Factors (HGFs)
    • 3.1.8. Tumor Necrosis Factors (TNFs)
    • 3.1.9. Interleukins
    • 3.1.10. Others
  • 3.2. Global Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 3.2.1. Oncology
    • 3.2.2. Hematology
    • 3.2.3. Wound Healing
    • 3.2.4. Dermatology
    • 3.2.5. Cardiovascular Disease & Diabetes
    • 3.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 3.2.7. Others
  • 3.3. Global Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Pharmaceutical and Biotechnology Companies
    • 3.3.2. Research Centres & Academic Institutes
    • 3.3.3. Contract Research Organisations
  • 3.4. Global Growth Factors Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Growth Factors Market Outlook, 2020-2033

  • 4.1. North America Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Transforming Growth Factor (TGF)
      • 4.1.1.1. Activin
      • 4.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 4.1.1.3. TGF-beta Proteins
    • 4.1.2. Epidermal Growth Factors (EGFs)
    • 4.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 4.1.4. Fibroblast Growth Factors (FGFs)
    • 4.1.5. Insulin-like Growth Factors (IGFs)
    • 4.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 4.1.7. Hepatocyte Growth Factors (HGFs)
    • 4.1.8. Tumor Necrosis Factors (TNFs)
    • 4.1.9. Interleukins
    • 4.1.10. Others
  • 4.2. North America Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 4.2.1. Oncology
    • 4.2.2. Hematology
    • 4.2.3. Wound Healing
    • 4.2.4. Dermatology
    • 4.2.5. Cardiovascular Disease & Diabetes
    • 4.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 4.2.7. Others
  • 4.3. North America Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Pharmaceutical and Biotechnology Companies
    • 4.3.2. Research Centres & Academic Institutes
    • 4.3.3. Contract Research Organisations
  • 4.4. North America Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Growth Factors Market Outlook, by Product Type, 2020-2033
    • 4.4.2. U.S. Growth Factors Market Outlook, by Application, 2020-2033
    • 4.4.3. U.S. Growth Factors Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Growth Factors Market Outlook, by Product Type, 2020-2033
    • 4.4.5. Canada Growth Factors Market Outlook, by Application, 2020-2033
    • 4.4.6. Canada Growth Factors Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Growth Factors Market Outlook, 2020-2033

  • 5.1. Europe Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Transforming Growth Factor (TGF)
      • 5.1.1.1. Activin
      • 5.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 5.1.1.3. TGF-beta Proteins
    • 5.1.2. Epidermal Growth Factors (EGFs)
    • 5.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 5.1.4. Fibroblast Growth Factors (FGFs)
    • 5.1.5. Insulin-like Growth Factors (IGFs)
    • 5.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 5.1.7. Hepatocyte Growth Factors (HGFs)
    • 5.1.8. Tumor Necrosis Factors (TNFs)
    • 5.1.9. Interleukins
    • 5.1.10. Others
  • 5.2. Europe Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 5.2.1. Oncology
    • 5.2.2. Hematology
    • 5.2.3. Wound Healing
    • 5.2.4. Dermatology
    • 5.2.5. Cardiovascular Disease & Diabetes
    • 5.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 5.2.7. Others
  • 5.3. Europe Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Pharmaceutical and Biotechnology Companies
    • 5.3.2. Research Centres & Academic Institutes
    • 5.3.3. Contract Research Organisations
  • 5.4. Europe Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.2. Germany Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.3. Germany Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.5. Italy Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.6. Italy Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.7. France Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.8. France Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.9. France Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.11. U.K. Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.12. U.K. Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.14. Spain Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.15. Spain Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.17. Russia Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.18. Russia Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.20. Rest of Europe Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.21. Rest of Europe Growth Factors Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Growth Factors Market Outlook, 2020-2033

  • 6.1. Asia Pacific Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Transforming Growth Factor (TGF)
      • 6.1.1.1. Activin
      • 6.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 6.1.1.3. TGF-beta Proteins
    • 6.1.2. Epidermal Growth Factors (EGFs)
    • 6.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 6.1.4. Fibroblast Growth Factors (FGFs)
    • 6.1.5. Insulin-like Growth Factors (IGFs)
    • 6.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 6.1.7. Hepatocyte Growth Factors (HGFs)
    • 6.1.8. Tumor Necrosis Factors (TNFs)
    • 6.1.9. Interleukins
    • 6.1.10. Others
  • 6.2. Asia Pacific Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 6.2.1. Oncology
    • 6.2.2. Hematology
    • 6.2.3. Wound Healing
    • 6.2.4. Dermatology
    • 6.2.5. Cardiovascular Disease & Diabetes
    • 6.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 6.2.7. Others
  • 6.3. Asia Pacific Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Pharmaceutical and Biotechnology Companies
    • 6.3.2. Research Centres & Academic Institutes
    • 6.3.3. Contract Research Organisations
  • 6.4. Asia Pacific Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.2. China Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.3. China Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.5. Japan Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.6. Japan Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.8. South Korea Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.9. South Korea Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.10. India Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.11. India Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.12. India Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.14. Southeast Asia Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.15. Southeast Asia Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.17. Rest of SAO Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.18. Rest of SAO Growth Factors Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Growth Factors Market Outlook, 2020-2033

  • 7.1. Latin America Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Transforming Growth Factor (TGF)
      • 7.1.1.1. Activin
      • 7.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 7.1.1.3. TGF-beta Proteins
    • 7.1.2. Epidermal Growth Factors (EGFs)
    • 7.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 7.1.4. Fibroblast Growth Factors (FGFs)
    • 7.1.5. Insulin-like Growth Factors (IGFs)
    • 7.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 7.1.7. Hepatocyte Growth Factors (HGFs)
    • 7.1.8. Tumor Necrosis Factors (TNFs)
    • 7.1.9. Interleukins
    • 7.1.10. Others
  • 7.2. Latin America Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 7.2.1. Oncology
    • 7.2.2. Hematology
    • 7.2.3. Wound Healing
    • 7.2.4. Dermatology
    • 7.2.5. Cardiovascular Disease & Diabetes
    • 7.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 7.2.7. Others
  • 7.3. Latin America Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Pharmaceutical and Biotechnology Companies
    • 7.3.2. Research Centres & Academic Institutes
    • 7.3.3. Contract Research Organisations
  • 7.4. Latin America Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.2. Brazil Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.3. Brazil Growth Factors Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.5. Mexico Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.6. Mexico Growth Factors Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.8. Argentina Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.9. Argentina Growth Factors Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.11. Rest of LATAM Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.12. Rest of LATAM Growth Factors Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Growth Factors Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Transforming Growth Factor (TGF)
      • 8.1.1.1. Activin
      • 8.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 8.1.1.3. TGF-beta Proteins
    • 8.1.2. Epidermal Growth Factors (EGFs)
    • 8.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 8.1.4. Fibroblast Growth Factors (FGFs)
    • 8.1.5. Insulin-like Growth Factors (IGFs)
    • 8.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 8.1.7. Hepatocyte Growth Factors (HGFs)
    • 8.1.8. Tumor Necrosis Factors (TNFs)
    • 8.1.9. Interleukins
    • 8.1.10. Others
  • 8.2. Middle East & Africa Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 8.2.1. Oncology
    • 8.2.2. Hematology
    • 8.2.3. Wound Healing
    • 8.2.4. Dermatology
    • 8.2.5. Cardiovascular Disease & Diabetes
    • 8.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 8.2.7. Others
  • 8.3. Middle East & Africa Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. Research Centres & Academic Institutes
    • 8.3.3. Contract Research Organisations
  • 8.4. Middle East & Africa Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.2. GCC Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.3. GCC Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.5. South Africa Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.6. South Africa Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.8. Egypt Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.9. Egypt Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.11. Nigeria Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.12. Nigeria Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.14. Rest of Middle East Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.15. Rest of Middle East Growth Factors Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Lonza Group AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.3. Merck KGaA
    • 9.4.4. Hoffmann-La Roche Ltd.
    • 9.4.5. Applied Biological Materials (abm), Inc.
    • 9.4.6. Abcam plc
    • 9.4.7. GE Healthcare
    • 9.4.8. Cell Signaling Technology, Inc.
    • 9.4.9. Meridian Bioscience Inc.
    • 9.4.10. Sartorius CellGenix GmbH

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations